Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 0.60 |
| ▸ | CA1 | P00915 | 1/20 | 0.59 |
| ▸ | CA2 | P00918 | 1/20 | 0.59 |
| ▸ | CA9 | Q16790 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | NAMPT | P43490 | 1/20 | 0.54 |
| ▸ | TERT | O14746 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23928144 | 0.84 | TP53 (0.67) | TP53CA1CA2CA9LMNA | |
| SCHEMBL8244969 | 0.80 | TP53 (0.72) | TP53CA1CA2CA9LMNA | |
| SCHEMBL5151404 | 0.79 | TP53 (0.74) | TP53CA1CA2CA9LMNA | |
| SCHEMBL23291354 | 0.77 | TP53 (0.55) | TP53CA1CA2CA9LMNA | |
| SCHEMBL15295566 | 0.76 | TP53 (0.56) | TP53CA1CA2CA9LMNA | |
| SCHEMBL23963292 | 0.76 | NAMPT (0.59) | TP53CA1CA2CA9LMNA | |
| SCHEMBL6491468 | 0.75 | MAPT (0.92) | TP53CA1CA2CA9LMNA | |
| SCHEMBL6486081 | 0.75 | TP53 (0.72) | TP53CA1CA2CA9LMNA | |
| SCHEMBL28703905 | 0.74 | LMNA (0.44) | LMNAMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL28102098 | 0.74 | NPC1 (0.49) | LMNAMAPTALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11845751-B2 | Triazolotriazine derivatives as A2A receptor antagonists | ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) | 2023-12-19 | — | — | US | disclosed |
| US-20210332055-A1 | TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS | ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) | 2021-10-28 | — | — | US | disclosed |
| EP-3814356-A1 | TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS | Zhejiang Vimgreen Pharmaceuticals, Ltd (CN) | 2021-05-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11845751-B2 | Triazolotriazine derivatives as A2A receptor antagonists | ADORA2A, ADORA1, ADORA3 | TP53 2047/4885CA1 1788/4885CA2 2300/4885 |
| US-20210332055-A1 | TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS | ADORA2A, ADORA1, ADORA3 | TP53 2047/4885CA1 1788/4885CA2 2300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.